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AbsTrACT
Objective The Tysabri Observational Programme 
(TOP), which began >10 years ago, is an open- label, 
multinational, prospective observational study evaluating 
the long- term safety and effectiveness of natalizumab in 
relapsing- remitting multiple sclerosis patients.
Methods These data provide a 10- year interim analysis 
of safety and effectiveness in TOP. annualised relapse 
rates (arrs) and disability progression/improvement 
were analysed using the Poisson model and the 
Kaplan- Meier method, respectively. analyses included 
patients on natalizumab and those who discontinued 
natalizumab but remained in TOP.
results as of november 2017, TOP included 6148 
patients. Overall, 829 patients (13.5%) experienced 
≥1 serious adverse event (sae), with infection the 
most common (4.1%). Fifty- three patients (0.9%) had 
confirmed progressive multifocal leukoencephalopathy. 
sae data were consistent with natalizumab’s known 
safety profile; no new safety signals were identified. 
a total of 3210 patients (52.2%) discontinued 
natalizumab; 2117 (34.4%) withdrew from TOP. Median 
time on natalizumab was 3.3 (range 0–11.6) years; 
median follow- up time was 5.2 (range 0–10.8) years. 
The on- natalizumab arr was 0.15, a 92.5% reduction 
from the year before initiation. Ten- year cumulative 
probabilities of disability worsening and improvement 
were 27.8% and 33.1%, respectively. On- natalizumab 
arrs were similar between patients who discontinued 
or remained on natalizumab, suggesting limited attrition 
bias.
Conclusions since the TOP 5- year interim analysis 
(December 2012), cohort size (6148 vs 4821), median 
exposure (3.3 vs 1.8 years) and median follow- up 
time (62 vs 26 months) have increased. This 10- year 
interim analysis further supports the robust real- world 
effectiveness and well- established safety profile of 
natalizumab.
Trial registration number ncT00493298.
InTrOduCTIOn
Natalizumab is a highly efficacious therapy for 
the treatment of relapsing- remitting multiple 
sclerosis (RRMS), as demonstrated in clinical 
trials and a number of real- world studies.1–3 Data 
collected during long- term real- world treatment 
complement and extend results from randomised 
clinical trials; real- world data also provide clini-
cians and patients practical benefit- risk informa-
tion when considering treatment options. The 
Tysabri Observational Programme (TOP), which 
began over 10 years ago, is the largest ongoing 
real- world study of natalizumab- treated patients 
with RRMS.
TOP collects data on safety and clinical 
outcomes in patients with RRMS initiating treat-
ment with natalizumab in clinical practice. In the 
5- year interim analysis of TOP, natalizumab treat-
ment was not associated with new safety signals.4 
The overall relapse rate was reduced significantly 
and remained low, and disability levels were 
stabilised and maintained over time.4 A separate 
analysis showed that the probability of disability 
worsening and transition to disability milestones 
remained low over approximately 5.5 years in 
TOP,5 while epoch analyses of TOP data indi-
cated better outcomes for patients who remained 
on natalizumab beyond 2 years of treatment 
compared with those who discontinued in the 
first 2 years.6 Thus, data from TOP have allowed 
investigators to address questions regarding the 
efficacy of natalizumab in the real- world clinical 
setting, with the ultimate goal of improving care 
for RRMS patients.
The current 10- year interim analysis of TOP 
extends the previous 5- year interim analysis with 
a larger population and longer duration of natal-
izumab exposure. In addition to reporting on 
long- term safety and effectiveness data, this study 
expands on the previous 5- year interim report by 
addressing the potential attrition bias inherent in 
long- term observational studies. To assess attri-
tion bias, effectiveness results were evaluated 
both in the group of patients with long- term 
natalizumab treatment (patients with ≥8 years of 
treatment) and in the group of patients who could 
have potentially received 8 years of natalizumab 
treatment had they not discontinued natalizumab. 
An additional analysis of attrition bias evaluated 
relapse rates during each year of natalizumab 
treatment in patients who discontinued or stayed 
on natalizumab beyond that year. Together, these 
10- year interim findings from TOP extend our 
knowledge of the safety and effectiveness profile 
of long- term natalizumab treatment.
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MeThOds
Patients
Patients were enrolled from Germany, the Czech Republic, 
Belgium, Italy, Canada, The Netherlands, Norway, Finland, 
France, Slovakia, Australia, Great Britain, Greece, Spain, 
Mexico, Portugal and Argentina. All patients met criteria for 
natalizumab prescription in their respective countries. The deci-
sion to treat with natalizumab was made prior to patient enrol-
ment. The protocol was approved by each centre’s independent 
ethics committee, and all patients provided written informed 
consent. The study was performed in accordance with the Decla-
ration of Helsinki.
study design
TOP is an ongoing, open- label, multinational, multicentre, 
prospective observational study of patients with RRMS initi-
ating natalizumab in real- world clinical practice settings. Patients 
enrolled in TOP were required to have a diagnosis of RRMS 
and to be natalizumab naïve or have received ≤3 doses of natal-
izumab in their lifetime at the time of enrolment. Details of the 
TOP study design have previously been published.4 This 10- year 
interim analysis includes data from study initiation (July 2007) 
through 1 November 2017.
endpoint and assessments
Demographic and clinical characteristics were recorded at enrol-
ment. Additional assessments took place at regularly scheduled 
clinical practice visits, which occurred approximately every 6 
months. Data on safety and relapses could also be collected at 
unscheduled visits to evaluate new or worsening neurological 
symptoms. Data collection was performed using a web- based 
electronic case report form. Patients who discontinued natali-
zumab were encouraged to remain in the study. If patients with-
drew from the study for any reason, physicians were asked to 
collect data on any serious adverse events (SAEs) for an addi-
tional 6 months where possible.
The primary endpoint was long- term safety (the incidence and 
pattern of SAEs) in patients receiving natalizumab. SAEs that 
occurred ≤6 months after the last natalizumab infusion were 
included, except for progressive multifocal leukoencephalopathy 
(PML) and death, which were included when they occurred at 
any time after the first dose of natalizumab. The relationship 
of each SAE to natalizumab treatment was determined by the 
reporting physician. Incidence rates of SAEs of interest (oppor-
tunistic infections, malignancy and PML) were examined per 
1000 patient- years overall as well as during two time intervals 
(≤3 years and >3 years), reflecting the median natalizumab 
treatment duration, to determine if incidence changed over time.
Secondary endpoints evaluated multiple sclerosis (MS) disease 
activity as measured by relapses and changes in disability. A 
clinical relapse was defined as new or recurrent neurolog-
ical symptoms not associated with fever lasting for ≥24 hours 
and followed by 30 days of stability or improvement. Relapses 
were recorded up to 84 days after the last dose of natalizumab. 
New or recurrent neurological symptoms that occurred <30 
days after the onset of a protocol- defined relapse were consid-
ered part of the same relapse. The occurrence and description 
of relapses, including details on relapses requiring the use of 
steroids or hospitalisation, were recorded by the prescribing 
clinician at regular clinical practice visits. Confirmed disability 
worsening was defined as an increase, confirmed 24 weeks later, 
of ≥0.5 point from a baseline Expanded Disability Status Scale 
(EDSS) score of ≥6.0, ≥1.0 point from a baseline EDSS score of 
≥1.0 to<6.0 or ≥1.5 points from a baseline EDSS score of 0.0. 
Confirmed disability improvement was defined as a decrease 
of ≥1.0 point from baseline score, confirmed 24 weeks later, 
among patients with baseline EDSS scores ≥2.0.7 Confirmation 
of 24- week worsening or improvement could occur up to 84 
days after the last dose of natalizumab.
statistical analysis
Baseline characteristics of TOP patients were summarised using 
descriptive statistics. Populations in the safety and effective-
ness analyses included patients who had provided informed 
consent, met study inclusion criteria and received ≥1 dose of 
natalizumab. On natalizumab, annualised relapse rates (ARRs) 
were analysed using a Poisson model with robust error variance. 
Analyses of relapse data in patients who did and did not discon-
tinue natalizumab treatment were performed to detect possible 
attrition bias. Cumulative probabilities of first relapse, disability 
worsening and disability improvement were estimated using the 
Kaplan- Meier method. Median EDSS scores over time (based on 
observed values) stratified by baseline EDSS score category were 
also analysed.
Associations between baseline factors and on- treatment ARRs 
were evaluated using a negative binomial model. Baseline vari-
ables included in an adjusted negative binomial model were 
age (≤40 or >40), the number of relapses in the year prior to 
natalizumab initiation (≤1 or >1), EDSS score (≤3.0 or >3.0) 
and the number of prior disease- modifying therapies (DMTs (0, 
1 or ≥2)). Associations between baseline factors and ARRs in 
the year prior to enrolment were similarly evaluated to assess 
pretreatment differences.
resulTs
Patient enrolment and baseline characteristics
As of 1 November 2017, 6148 patients from 17 countries 
were enrolled in TOP. Baseline characteristics are summarised 
in table 1. In the overall population, the median disease dura-
tion at baseline was 7.8 years (range 0–48 years), and 3245 
patients (52.8%) had EDSS scores >3.0. Most patients (84.5%) 
had used another DMT prior to starting natalizumab. Anti–JC 
virus (JCV) antibody status was tested at enrolment in 4339 of 
6148 patients (70.6%). A total of 2102 patients (34.2%) were 
anti- JCV antibody positive and 2230 (36.3%) were anti- JCV 
antibody negative.
Baseline characteristics are presented not only for the overall 
population, which includes all patients who enrolled at any time 
point, but also for patients who had received ≥8 years of natal-
izumab treatment at the time of the data cut (the ≥8- year treat-
ment cohort) and patients who enrolled >8 years prior to the 
data cut but who discontinued natalizumab before completing 8 
years of treatment (the <8- year treatment cohort). Characteris-
tics were generally similar between the three groups; however, 
patients in the ≥8- year treatment cohort appeared to have had a 
slightly earlier disease course, as evidenced by lower age, disease 
duration, EDSS score and prior DMT use duration than those 
in the <8- year treatment cohort. In addition, the proportion 
of patients who were anti- JCV antibody negative at baseline 
appeared to be greater in the ≥8- year treatment cohort (59.9%) 
than in the overall population (36.3%) or the <8- year treatment 
cohort (13.8%).
Patient enrolment and disposition data are shown in figure 1. 
Median time on natalizumab was 3.3 (range 0–11.6) years. 
Median follow- up time was 5.2 (range 0–10.8) years. As of 
1 November 2017, 3210 patients (52.2%) had discontinued 
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Table 1 Baseline demographics and clinical characteristics
Characteristic
Overall 
population
(n=6148)
≥8- year 
treatment 
cohort
(n=491)
<8- year 
treatment 
cohort
(n=1056)
Age at baseline, mean (SD), 
years
37.1 (9.8) 35.9 (9.2) 38.7 (9.8)
Female, n (%) 4430 (72.1) 366 (74.5) 755 (71.5)
Relapses in year prior to 
natalizumab initiation
  Mean (SD) 2.0 (1.0) 2.0 (1.1) 2.0 (1.1)
  n (%)
  ≤1 2094 (34.1) 164 (33.4) 395 (37.4)
  >1 4054 (65.9) 327 (66.6) 661 (62.6)
Baseline EDSS score
  Mean (SD) 3.5 (1.6) 3.3 (1.5) 3.8 (1.8)
  ≤3.0, n (%) 2843 (46.2) 240 (48.9) 423 (40.1)
  >3.0, n (%) 3245 (52.8) 250 (50.9) 625 (59.2)
  Unknown, n (%) 60 (1.0) 1 (0.2) 8 (0.8)
Disease duration at baseline, 
median (range), years
7.8 (0 to 48) 7.6 (0 to 39) 8.8 (0 to 48)
Treatment duration prior to 
natalizumab initiation, years
  Mean (SD) 4.0 (3.9) 3.8 (3.5) 3.8 (3.5)
  Median (range) 2.9 (0 to 22) 2.7 (0 to 16) 2.8 (0 to 17)
Prior DMTs, n (%)
  0 952 (15.5) 65 (13.2) 152 (14.4)
  1 2897 (47.1) 241 (49.1) 514 (48.7)
  ≥2 2299 (37.4) 185 (37.7) 390 (36.9)
Prior MS DMT used, n (%)*
  Interferon beta- 1a 
formulations
4494 (73.1) 378 (77.0) 811 (76.8)
  Glatiramer acetate 2034 (33.1) 154 (31.4) 322 (30.5)
  Fingolimod 233 (3.8) 1 (0.2) 3 (0.3)
  Dimethyl fumarate 44 (0.7) 0 (0) 2 (0.2)
  Teriflunomide 25 (0.4) 1 (0.2) 1 (0.1)
  Alemtuzumab 2 (<0.1) 1 (0.2) 0 (0)
Prior immunosuppressant use, 
n (%)
983 (16.0) 82 (16.7) 175 (16.6)
Natalizumab doses prior to 
enrolment, mean (SD)
1.1 (1.1) 1.2 (1.2) 1.2 (1.2)
Patients who were anti- JCV 
antibody positive, n (%)
2102 (34.2)† 170 (34.6)† 293 (27.7)†
Patients who were anti- JCV 
antibody negative, n (%)
2230 (36.3)† 294 (59.9)† 146 (13.8)†
*Patients may have used >1 DMT.
†Anti- JCV antibody status at enrolment was tested in 4339 patients in the overall 
population, 469 patients in the ≥8- year treatment cohort and 440 patients in the 
<8- year treatment cohort.
DMT, disease- modifying therapy; EDSS, Expanded Disability Status Scale; JCV, JC 
virus; MS, multiple sclerosis.
natalizumab and 2117 (34.4%) had withdrawn from TOP. Of 
the patients who discontinued natalizumab treatment, 1093 
(34.0%) remained in TOP. The most common reasons for treat-
ment discontinuation were positive anti- JCV antibody serostatus 
(1487 of 3210 patients (46.3%)), patient decision (831 of 
3210 patients (25.9%)) and medication change (616 of 3210 
patients (19.2%)). Among patients who discontinued natali-
zumab treatment, rates of discontinuation due to reported insuf-
ficient efficacy were low and not markedly different between 
patient cohorts (12.8% in the overall population and 13.7% 
in the <8- year treatment cohort). The most common reasons 
for withdrawal from TOP were other (543 of 2117 (25.6%)), 
patient decision (454 of 2117 (21.4%)) and lost to follow- up 
(326 of 2117 (15.4%)).
At enrolment, 2102 patients (34.2%) were anti- JCV antibody 
positive and 2230 (36.3%) were anti- JCV antibody negative. 
Anti- JCV antibody serostatus was not tested at enrolment in 
1809 patients (29.4%) and serostatus was missing from seven 
patients who were tested at enrolment (0.1%). Of the 2230 
subjects who were anti- JCV antibody negative at enrolment, 565 
(25.3%) had a change of serostatus to positive on treatment. In 
the 2230 known baseline anti- JCV antibody negative patients, 
there was a total of 9963.27 person- years of exposure, with an 
incidence of 5.7% per person- year.
safety
Overall, 829 of 6148 patients (13.5%) experienced ≥1 SAE and 
290 patients (4.7%) experienced ≥1 SAE considered related or 
possibly related to natalizumab treatment. Table 2 lists SAEs 
by System Organ Class and Medical Dictionary for Regulatory 
Activities preferred terms for SAEs that occurred in >5 patients. 
The most common SAEs were infections and infestations, with 
an incidence of 4.1%; PML, pneumonia, urinary tract infection 
and herpes zoster were the most commonly reported infections 
(table 2). Of note, the rates of development of malignancies and 
opportunistic infections, with the exception of PML, remained 
very low.
Opportunistic infections were classified based on the presence 
of an identifiable organism as well as clinical symptoms. Eleven 
patients (0.2%) had 14 events defined as opportunistic infections 
other than PML, including herpes zoster, meningitis herpes, 
encephalitis, herpes simplex encephalitis, herpes zoster dissem-
inated, listeria meningitis (sepsis), pneumonia and pulmonary 
Mycobacterium kansasii infection (see online supplementary 
etable 1). The median time to onset for opportunistic infections 
was 14 months from natalizumab initiation, with a range of 3 
months to 5 years. Three patients had two events each: one with 
pneumonia and staphylococcal sepsis; one with tuberculosis and 
M. kansasii; and one with listeria sepsis (meningitis) and listeria 
meningitis (sepsis). Herpes zoster was reported by three patients, 
herpes meningitis was reported in two patients and the other 
infections were reported in one patient each. The events were 
of viral aetiology in eight patients and were bacterial in three 
patients. Eight cases were referred to the central nervous system 
(CNS) and three were referred to non- CNS sites.
In the entire cohort, 53 patients (0.9%) had confirmed PML. 
PML patients received a median of 42 doses or months of expo-
sure (range 11–124); 36 of 53 PML cases (67.9%) occurred in 
patients receiving natalizumab for >3 years. The overall PML 
incidence rate per 1000 patient- years was 2.034 (95% CI 1.554 
to 2.662). Prior immunosuppressant use was reported by 14 
PML patients (26.4%). Of the 36 PML cases with reported 
anti- JCV antibody serostatus available 6 months prior to PML 
development, 35 (97.2%) were confirmed positive. Within the 
PML cohort, there were two identified cases of JCV- associated 
granule cell neuropathy. As of 1 November 2017, 44 of 53 
patients diagnosed with PML (83.0%) were alive.
Overall, there were 66 patients (1.1%) with 39 types of 
malignancies. The median time to onset for malignancy was 65 
months, with a range of 2 months to 8 years. Of the reported 
malignancies, four were fatal (lung neoplasm, adenocarcinoma 
of colon, choroid melanoma and metastatic breast cancer). 
Breast cancer was the most common malignancy, affecting 19 
patients (including invasive ductal breast carcinoma in five 
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Figure 1 annual accounting of patients in TOP. Patients who entered TOP in a given year are shown in green, whereas the other categories are combined 
to indicate the cumulative number of patients in TOP. Patients who received natalizumab in TOP and continued natalizumab treatment through 1 november 
of that year are shown in dark blue. Patients who discontinued natalizumab but remained in TOP through 1 november of that year are shown in light blue. 
cumulative numbers of patients who withdrew over the study duration are shown in orange. *accounting is shown for study start (July 2007) through 1 
november 2017. For all years, patients enrolled after 1 november are accounted for in the following year. TOP, Tysabri Observational Programme.
patients and metastatic breast cancer in two patients). The rate 
of breast cancer was 86.7 per 100 000 patient- years, with a 95% 
CI of 52.2 to 135.4 per 100 000 patient- years, encompassing 
the rates of 123.8 per 100 000 patient- years in the Surveillance, 
Epidemiology and End Results (SEER) database8 and 80.3 per 
100 000 person- years in the Global Cancer Incidence, Mortality 
and Prevalence (GLOBOCAN database).9 Other reported malig-
nancies included papillary thyroid cancer in four patients, colon 
cancer in four patients, renal cancer in three patients and chronic 
lymphocytic leukaemia in three patients. CNS tumours (one 
glioblastoma and one oligodendroglioma) were diagnosed in 
two patients. The remaining malignancies were each diagnosed 
in ≤2 patients (see online supplementary etable 2).
Incidence rates of SAEs of interest (opportunistic infections, 
PML and malignancy) were evaluated during two time epochs 
of natalizumab use (≤3 years and >3 years) to account for the 
impact of prolonged exposure to natalizumab (table 3). Overall, 
incidence rates per 1000 patient- years for all three SAEs were 
relatively low, and ≤1.02% of patients reported these SAEs. 
When evaluating by time epoch, opportunistic infection inci-
dence rates were higher during the first 3 years of natalizumab 
treatment than during later natalizumab treatment. Incidence 
rates appeared to increase slightly for malignancy during the 
later epoch, though the CIs for both time epochs overlapped. 
PML incidence rates were approximately three times higher in 
the second time epoch than in the first.
Other safety events included SAEs related to hypersensitivity 
reactions (n=40, representing 0.7% of patients), with four cases 
reported as anaphylactic reaction, three cases as anaphylactoid 
reaction, five cases as anaphylactic shock and the remaining 28 
cases as hypersensitivity. Just over half of the cases (21 of 40 
(53%)) occurred within the first three doses. Hypersensitivity 
led to treatment discontinuation in 36 patients and there were 
no associated fatalities. Two cases were considered unrelated 
to natalizumab: in one case, the anaphylactic reaction was 
attributed to another drug and in the other case, the anaphylactic 
shock was attributed to nut ingestion.
Twelve hepatic events (representing 0.2% of patients) were 
reported during the study. All were serious except for one unre-
lated case of abnormal hepatic function, which remained unre-
solved even though treatment was discontinued. These hepatic 
events comprised four cases of drug- induced liver injury (two of 
which were related to natalizumab), two cases of autoimmune 
hepatitis and single cases of acute hepatic failure, hepatitis, hepa-
titis fulminant and liver injury. Median time to onset of hepatic 
events was 7.6 months, with a range of 1 to 10 months, and 
natalizumab was discontinued in all cases.
There were 30 deaths (0.5%) during the study. The reporting 
physician classified the deaths as treatment related in eight of 
these cases: four cases of PML, two cases of immune reconstitu-
tion inflammatory syndrome (one of which was combined with 
MS relapse) and one case each of metastatic breast cancer and 
autonomic nervous system imbalance.
effectiveness
Relapses
During the 10 years of follow- up, the on- natalizumab ARR was 
0.15 (95% CI 0.14 to 0.15), a 92.5% reduction from the ARR 
of 1.99 (95% CI 1.97 to 2.02) in the year prior to starting natal-
izumab. Patients had large reductions in on- natalizumab ARR 
regardless of age category at baseline, baseline EDSS score cate-
gory or the number of DMTs used prior to natalizumab initiation 
(see online supplementary etable 3). However, patients with a 
lower baseline EDSS score (≤3.0 vs >3.0), fewer prior DMTs 
(0 vs 1; 0 vs ≥2; 1 vs ≥2) or fewer relapses in the year prior 
to treatment (≤1 vs >1) had significantly lower on- natalizumab 
ARRs (online supplementary etable 3). The cumulative proba-
bility of remaining relapse free at 10 years was 45.8%.
In the overall population, the ARR decreased from 1.99 at 
baseline to 0.24 at 1 year of natalizumab treatment, and ARRs 
remained ≤0.20 from 2 to 10 years (figure 2). Similar results 
were observed for the other cohorts: the ARR decreased from 
2.04 to 0.21 in the ≥8- year treatment cohort and from 1.97 to 
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Table 2 Incidence of serious adverse events in TOP*
event, n (%) n=6148
Patients with ≥1 SAE 829 (13.5)
SAEs by SOC and MedDRA preferred term reported in >5 patients*
Infections and infestations 254 (4.1)
  PML, confirmed 53 (0.9)
  Pneumonia 23 (0.4)
  Urinary tract infection 20 (0.3)
  Herpes zoster 17 (0.3)
  Escherichia urinary tract infection 12 (0.2)
  Pyelonephritis 10 (0.2)
  Appendicitis 8 (0.1)
  Diverticulitis 6 (0.1)
  Gastroenteritis 6 (0.1)
  Sepsis 6 (0.1)
Nervous system† 142 (2.3)
  Epilepsy 18 (0.3)
  MS 15 (0.2)
  Syncope 8 (0.1)
  Headache 7 (0.1)
  Sciatica 6 (0.1)
  Uhthoff’s phenomenon 6 (0.1)
Immune system disorders 92 (1.5)
  Immune reconstitution inflammatory syndrome‡ 54 (0.9)
  Hypersensitivity 26 (0.4)
Neoplasms benign, malignant and unspecified (including cysts and 
polyps)
88 (1.4)
  Breast cancer 12 (0.2)
  Uterine leiomyoma 9 (0.1)
Injury, poisoning and procedural complications 75 (1.2)
  Fall 19 (0.3)
Psychiatric disorders 69 (1.1)
  Depression 18 (0.3)
  Suicide attempt 11 (0.2)
  Completed suicide 7 (0.1)
Pregnancy, puerperium and perinatal conditions 55 (0.9)
  Abortion spontaneous 37 (0.6)
Musculoskeletal and connective tissue disorders 48 (0.8)
  Intervertebral disc protrusion 12 (0.2)
  Back pain 8 (0.1)
Surgical and medical procedures 37 (0.6)
  Caesarean section 8 (0.1)
General disorders and administration site conditions 32 (0.5)
  Fever 6 (0.1)
Respiratory, thoracic and mediastinal disorders 26 (0.4)
  Pulmonary embolism 10 (0.2)
Hepatobiliary disorders 24 (0.4)
  Cholelithiasis 7 (0.1)
Vascular disorders 19 (0.3)
  Deep vein thrombosis 6 (0.1)
*Each patient was counted only once within each preferred term.
†MS relapse was also reported as an SAE in 20 patients (0.3%).
‡One case of immune reconstitution inflammatory syndrome was not associated 
with PML.
MedDRA, Medical Dictionary for Regulatory Activities; MS, multiple sclerosis; PML, 
progressive multifocal leukoencephalopathy; SAE, serious adverse event; SOC, 
system organ class; TOP, Tysabri Observational Programme.
0.26 in the <8- year treatment cohort. For both cohorts, ARRs 
remained ≤0.21 in subsequent years. In comparisons of ARR 
between patients who continued natalizumab or discontinued 
natalizumab in the following year, ARRs were generally similar, 
and the on- natalizumab ARR of both groups remained <0.15 
(see online supplementary efigure 1).
Disability
At 10 years, the cumulative probability of 24- week confirmed 
disability worsening was 27.8% (figure 3A). At 10 years, the 
cumulative probability of 24- week confirmed disability improve-
ment was 33.1% (figure 3B). Of the 5179 patients with base-
line EDSS scores ≥2.0, 1210 (23.4%) experienced a confirmed 
disability improvement event.
Box plots of EDSS score changes for each year of natalizumab 
treatment showed that EDSS scores were stable over the 10 years 
of follow- up (figure 4). When stratified by baseline EDSS score 
category, patients in each group had mean EDSS score changes 
of <1.0 from baseline over 10 years (see online supplementary 
efigure 2). At 8 years, the distribution of change in EDSS from 
baseline in the ≥8- year treatment cohort indicated similarly 
small change for the majority of patients (see online supplemen-
tary efigure 3).
dIsCussIOn
This TOP 10- year interim analysis reports on the long- term 
safety and effectiveness of natalizumab in the largest ongoing 
real- world study of natalizumab- treated RRMS patients. As of 
November 2017, 6148 patients were enrolled in TOP, and they 
had been exposed to natalizumab for a median of 3.3 (range 
0–11.6) years. Safety findings were consistent with the current 
safety profile of natalizumab, and no new safety concerns were 
identified.2 4 10 Natalizumab- treated patients exhibited signifi-
cant disease control over the course of the study, as evidenced by 
on- natalizumab ARRs that were reduced and remained low and 
EDSS scores that remained stable over 10 years.
Over the course of natalizumab treatment, >85% of patients 
had no SAEs. In those patients who did experience an SAE, infec-
tion was the most reported SAE, occurring in 4.1% of patients. 
Opportunistic infections other than PML were reported in a very 
small proportion of patients (0.2%), which is consistent with the 
rate of <1% observed in clinical trials.10 Low incidence rates 
were also observed for malignancy (1.1%); breast cancer was the 
most common neoplasm (n=19) and occurred at a rate (86.7 per 
100 000 patient- years) lower than the expected European age- 
standardised incidence rate (94.2 per 100 000)11 and in line with 
the background rates reported by SEER8 and GLOBOCAN.9
The incidence of PML in TOP was 8.6 cases per 1000 patients 
overall and 2.0 per 1000 patient- years of natalizumab exposure. 
Of the 53 confirmed cases, 36 (67.9%) occurred in patients 
receiving natalizumab for >3 years and 14 (26.4%) occurred 
in patients reporting prior immunosuppressant use. Of the 36 
cases with reported anti- JCV antibody serostatus 6 months prior 
to PML development, 35 were positive. While previous expo-
sure to JCV is a requirement for PML development, the assay 
measures only current presence of antibodies to JCV, is limited 
to seroconversion occurring from last JCV testing to PML devel-
opment and has an estimated false- negative rate of 2.2%.12 
These results are in line with the current understanding of the 
risk factors for PML (duration of treatment, prior immunosup-
pressant use and the presence of anti- JCV antibodies).13 14 The 
published estimated annualised incidence of PML ranges from 
0.0001 (0.1 cases/1000 patients) in anti- JCV antibody negative 
patients to 0.008 (8 cases/1000 patients) in anti- JCV antibody–
positive patients with prior immunosuppressant use and 49–60 
months of natalizumab exposure.15 It should be noted that there 
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Table 3 Incidence of opportunistic infection, malignancy and PML during the first 3 years of natalizumab treatment, after 3 years of natalizumab 
treatment and across the entire treatment period
event ≤3 years (n=6148) >3 years (n=3719) Overall (n=6148)
Patient- years of follow- up* 15 773.19 10 233.77 26 060.25
Opportunistic infection
  Patients with an event, n (%) 10 (0.16) 1 (0.03) 11 (0.18)
  Incidence rate (95% CI)† 0.634 (0.341 to 1.178) 0.098 (0.014 to 0.694) 0.422 (0.234 to 
0.762)
PML
  Patients with an event, n (%) 17 (0.28) 36 (0.97) 53 (0.86)
  Incidence rate per 1000 patient- years (95% CI)† 1.078 (0.67 to 1.734) 3.518 (2.537 to 4.877) 2.034 (1.554 to 
2.662)
Malignancy
  Patients with an event, n (%) 35 (0.57) 28 (0.75) 63 (1.02)
  Incidence rate (95% CI)† 2.219 (1.593 to 3.090) 2.736 (1.889 to 3.963) 2.417 (1.889 to 
3.095)
Serious adverse event timing is determined based on event start date. Patients with >1 event are counted only once.
*Based on the time from the first dose of natalizumab until the last natalizumab dosing date + 6 months.
†Calculated as (1000 × number of patients with an event) / (total patient- years of follow- up). Exact CIs are calculated based on the Poisson distribution.
PML, progressive multifocal leukoencephalopathy.
Figure 2 annualised relapse rate (arr) during each year of natalizumab treatment.
are few data on PML rates beyond 6 years of treatment in the 
postmarketing setting.
Epoch analyses of opportunistic infection, PML and malig-
nancy support an impact of extended exposure on the incidence 
of these safety events. Over 10 years in TOP, there was a slight 
increase in malignancy and PML as expected due to age- related 
increases in cancer risk16 and the impact of longer treatment 
duration on PML risk.13 14 However, the incidence of oppor-
tunistic infections remained low over time, and such infections 
tended to occur within the first few years of treatment.
Substantial improvements in ARR were seen within the first 
year of natalizumab treatment, and ARR remained low over 
the duration of follow- up. Notably, comparable results were 
observed in the cohorts that received ≥8 years and <8 years 
of natalizumab treatment; yearly relapse rates in patients who 
discontinued in the following year and those who remained on 
treatment were similar; and lack of efficacy was rarely given 
as the reason for natalizumab discontinuation. This analysis 
of attrition bias is limited by the small number of patients in 
the <8- year treatment group, which decreased from 1056 at 
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Figure 3 estimated cumulative probability of 24- week confirmed (a) disability worsening and (B) disability improvement over 10 years in participants with 
eDss ≥2.0 at baseline. eDss, expanded Disability status scale.
Figure 4 Box plot of expanded Disability status scale (eDss) scores from enrolment to year 10 in the overall population. The bottom and top edges of the 
box represent the interquartile range (iQr). The line inside the box represents the median value, which is also indicated by the number. The diamond inside 
the box indicates the mean value. The whiskers of the box are drawn from the box to the most extreme point that is ≤1.5 × iQr. circles above the whiskers 
indicate outliers.
baseline to 389 at 8 years. Collectively, however, these data 
suggest that in TOP, the practice of discontinuing patients with 
worse efficacy outcomes is limited and therefore attrition bias is 
unlikely to account for the observed long- term efficacy results.
After initiation of natalizumab, ARR decreased markedly 
regardless of baseline characteristics such as disease activity or 
prior DMT use. However, patients earlier in the disease course 
at baseline, as indicated by lower baseline EDSS score and less 
prior DMT use, showed significantly lower on- natalizumab 
ARRs. Similarly, in the TOP 5- year interim analysis, patients 
with lower EDSS at baseline and less prior DMT use had lower 
on- natalizumab relapse rates.4 These results from TOP under-
score the high efficacy of natalizumab in all populations with 
RRMS.
This 10- year interim analysis of TOP extends the previous 
analysis4 with a larger population (6148 vs 4821 patients), a 
longer natalizumab exposure duration (median 3.3 vs 1.8 years) 
and a longer follow- up time (median 62 vs 26 months). Further-
more, TOP is unique in its duration; it includes nearly 500 
patients treated with natalizumab for ≥8 years and has recently 
been extended for a further 5 years in 2019. TOP generates valu-
able prospective, real- world outcome information on the risks 
and benefits of long- term natalizumab treatment. The results 
demonstrate excellent long- term safety and substantial disease 
control. Long- term treatment was associated with a very low risk 
of non- PML opportunistic infection and cancer rates similar to 
those expected in the general population. The planned continued 
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follow- up of TOP patients for up to 15 years will provide further 
data on real- world outcomes in natalizumab- treated patients.
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